• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据心血管风险对老年芬兰人进行的他汀类药物使用分层。

Statin use among older Finns stratified according to cardiovascular risk.

机构信息

Department of Pharmacology, Drug Development and Therapeutics, University of Turku, 20014 Turku, Finland.

出版信息

Eur J Clin Pharmacol. 2013 Feb;69(2):261-7. doi: 10.1007/s00228-012-1328-0. Epub 2012 Jun 17.

DOI:10.1007/s00228-012-1328-0
PMID:22706622
Abstract

PURPOSE

Statin use has increased in older age groups, although there is little evidence for the benefits of statin therapy in the elderly, especially in low-risk persons. The aim of this paper is to describe recent trends in the prevalence and incidence of statin use among the Finnish older population, according to the person's estimated cardiovascular (CV) event risk.

METHODS

We conducted a register study covering the whole community-dwelling population of Finland, aged >70 years in 2000-2008 (N = 883,051). Data on reimbursed purchases of statins, antidiabetic and CV drugs, and pre-existing CV diseases were retrieved from comprehensive national registers. We stratified each person into low, moderate or high CV risk category, and according to age (70-74, 75-79, and >80 years) and sex.

RESULTS

Between 2000 and 2008, the age-sex-standardized prevalence of statin use tripled from 12.2 % to 38.7 % (rate ratio 3.0, 95 % CI 3.0-3.1), and the incidence almost doubled (from 3.7 % to 6.8 %; rate ratio 1.8, 95 % CI 1.8-1.9). The prevalence and incidence of statin use were consistently highest among high-risk persons. The greatest relative increases were observed in persons aged >80 years and in those at low risk; however, the proportion of statin users at low CV risk remained the same (∼7 % of all users).

CONCLUSIONS

Statin prescribing is shifting towards older age groups. A substantial increase in prevalence and incidence was seen across all risk categories, but the channeling of statin use towards high-risk persons remained unchanged.

摘要

目的

尽管在老年人中他汀类药物治疗的益处证据有限,尤其是在低危人群中,他汀类药物的使用在老年人群体中有所增加。本文旨在根据个体的心血管(CV)事件风险描述芬兰老年人群中他汀类药物使用的流行率和发生率的近期趋势。

方法

我们进行了一项基于登记的研究,涵盖了 2000-2008 年芬兰年龄>70 岁的所有社区居住人群(n=883051)。从综合国家登记册中检索了他汀类药物、降糖药和心血管药物的报销购买情况以及预先存在的心血管疾病数据。我们将每个人分为低、中或高 CV 风险类别,并根据年龄(70-74、75-79 和>80 岁)和性别进行分层。

结果

2000 年至 2008 年间,他汀类药物使用率的年龄-性别标准化患病率从 12.2%增至 38.7%(率比 3.0,95%CI 3.0-3.1),发病率几乎翻了一番(从 3.7%增至 6.8%;率比 1.8,95%CI 1.8-1.9)。高风险人群的他汀类药物使用率始终最高。在>80 岁的人群和低危人群中观察到相对增幅最大;然而,低 CV 风险的他汀类药物使用者比例保持不变(约占所有使用者的 7%)。

结论

他汀类药物的处方正在向老年人群转移。所有风险类别中均出现了使用率和发病率的大幅增加,但将他汀类药物用于高危人群的趋势没有改变。

相似文献

1
Statin use among older Finns stratified according to cardiovascular risk.根据心血管风险对老年芬兰人进行的他汀类药物使用分层。
Eur J Clin Pharmacol. 2013 Feb;69(2):261-7. doi: 10.1007/s00228-012-1328-0. Epub 2012 Jun 17.
2
Statin prescribing according to gender, age and indication: what about the benefit-risk balance?根据性别、年龄和适应症开具他汀类药物处方:获益-风险平衡情况如何?
J Eval Clin Pract. 2016 Apr;22(2):235-46. doi: 10.1111/jep.12462. Epub 2015 Oct 8.
3
Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.荷兰老年人他汀类药物的处方情况:一项基于药房数据库的时间趋势研究。
Drugs Aging. 2010 Jul 1;27(7):589-96. doi: 10.2165/11537330-000000000-00000.
4
Statin use in Canadians: trends, determinants and persistence.加拿大人使用他汀类药物的情况:趋势、决定因素及持续性。
Can J Public Health. 2007 Sep-Oct;98(5):412-6. doi: 10.1007/BF03405430.
5
A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data.澳大利亚老年人中他汀类药物使用的 10 年趋势:基于国家药房理赔数据的分析。
Cardiovasc Drugs Ther. 2018 Jun;32(3):265-272. doi: 10.1007/s10557-018-6794-x.
6
Channelling of statin use towards low-risk population and patients with diabetes.将他汀类药物的使用引导至低危人群和糖尿病患者。
Basic Clin Pharmacol Toxicol. 2013 Sep;113(3):173-8. doi: 10.1111/bcpt.12075. Epub 2013 May 20.
7
[Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011].[德国他汀类药物使用流行率的变化——1997 - 1999年和2008 - 2011年全国健康访谈与检查调查结果]
Z Evid Fortbild Qual Gesundhwes. 2017 May;122:22-31. doi: 10.1016/j.zefq.2017.04.001. Epub 2017 May 13.
8
Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.1999年至2013年间二级预防中他汀类药物使用情况及心血管事件复发率的时间趋势:一项基于注册登记的研究
BMC Cardiovasc Disord. 2018 Nov 6;18(1):209. doi: 10.1186/s12872-018-0941-y.
9
Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.爱尔兰他汀类药物使用情况及其预测因素的横断面分析,重点关注心血管疾病的一级预防。
BMJ Open. 2018 Feb 8;8(2):e018524. doi: 10.1136/bmjopen-2017-018524.
10
Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes.为临床医生提供患者的 10 年心血管风险可改善其他汀类药物的开具情况:使用临床病例进行的真实验。
BMC Cardiovasc Disord. 2013 Oct 22;13:90. doi: 10.1186/1471-2261-13-90.

引用本文的文献

1
Statin treatment for primary and secondary prevention in elderly patients-a cross-sectional study in Stockholm, Sweden.他汀类药物治疗老年患者的一级和二级预防-瑞典斯德哥尔摩的一项横断面研究。
Eur J Clin Pharmacol. 2024 Oct;80(10):1571-1580. doi: 10.1007/s00228-024-03724-3. Epub 2024 Jul 16.
2
Incidence in pharmacoepidemiology: A conceptual framework for incidence of a single substance or group of substances with statins as an example.药物流行病学中的发生率:以他汀类药物为例的单一物质或物质组发生率的概念框架。
Basic Clin Pharmacol Toxicol. 2023 Feb;132(2):171-179. doi: 10.1111/bcpt.13816. Epub 2022 Dec 5.
3
Use of statins in the elderly according to age and indication-a cross-sectional population-based register study.

本文引用的文献

1
Editor's Note--to make the case--evidence is required: comment on "Making the case for selective use of statins in the primary prevention setting".编者按——提出理由——需要证据:对“在一级预防中选择性使用他汀类药物的理由”的评论
Arch Intern Med. 2011 Sep 26;171(17):1594. doi: 10.1001/archinternmed.2011.409.
2
Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy.基于适应证等级的药物利用:一种药物流行病学方法。
Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1027-35. doi: 10.1002/pds.2195. Epub 2011 Aug 8.
3
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
根据年龄和适应证使用他汀类药物的情况-一项基于人群的横断面登记研究。
Eur J Clin Pharmacol. 2019 Jul;75(7):959-967. doi: 10.1007/s00228-019-02645-w. Epub 2019 Mar 3.
4
How Common is Statin Use in the Oldest Old?他汀类药物在高龄老人中的使用有多普遍?
Drugs Aging. 2018 Aug;35(8):679-686. doi: 10.1007/s40266-018-0567-x.
5
Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data.英国他汀类药物用于心血管疾病一级预防的处方时间趋势:一项使用健康改善网络初级保健数据的队列研究
Clin Epidemiol. 2016 May 27;8:123-32. doi: 10.2147/CLEP.S104258. eCollection 2016.
6
Primary prevention of cardiovascular disease with statins in the elderly.老年人群用他汀类药物进行心血管疾病一级预防。
Curr Atheroscler Rep. 2014 Jul;16(7):420. doi: 10.1007/s11883-014-0420-6.
7
Trends in statin therapy initiation during the period 2000-2010 in Israel.2000年至2010年期间以色列他汀类药物治疗起始情况的趋势。
Eur J Clin Pharmacol. 2014 May;70(5):557-64. doi: 10.1007/s00228-013-1637-y. Epub 2014 Jan 25.
8
[Lipid lowering therapy in geriatric patients].老年患者的降脂治疗
Z Gerontol Geriatr. 2013 Aug;46(6):577-85; quiz 586-7. doi: 10.1007/s00391-013-0516-6.
ESC/EAS 血脂异常管理指南:欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
4
Criteria for drug selection in frail elderly persons. frail 老年人药物选择的标准。
Drugs Aging. 2011 May 1;28(5):391-402. doi: 10.2165/11587200-000000000-00000.
5
Dynamics of long-term statin therapy.他汀类药物长期治疗的动态变化。
Eur J Clin Pharmacol. 2011 Sep;67(9):925-31. doi: 10.1007/s00228-011-1019-2. Epub 2011 Mar 16.
6
Statins for the primary prevention of cardiovascular disease.他汀类药物用于心血管疾病的一级预防。
Cochrane Database Syst Rev. 2011 Jan 19(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
7
Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment?1997 年至 2006 年期间英国男性和女性首次心肌梗死后使用他汀类药物的情况:谁开始治疗,谁继续治疗?
Nutr Metab Cardiovasc Dis. 2012 May;22(5):400-8. doi: 10.1016/j.numecd.2010.09.010. Epub 2010 Dec 30.
8
Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.他汀类药物在老年人中的应用与血脂水平:2001 至 2006 年全国健康和营养调查。
J Clin Lipidol. 2010 Nov-Dec;4(6):483-90. doi: 10.1016/j.jacl.2010.10.002. Epub 2010 Oct 13.
9
The impact of ageing and changing utilization patterns on future cardiovascular drug expenditure: a pharmacoepidemiological projection approach.老龄化和利用模式变化对未来心血管药物支出的影响:药物流行病学预测方法。
Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1276-86. doi: 10.1002/pds.2039. Epub 2010 Oct 15.
10
Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds.降脂治疗到底?对 80 岁以上人群胆固醇与死亡率的观察性研究和 RCT 的综述。
Age Ageing. 2010 Nov;39(6):674-80. doi: 10.1093/ageing/afq129. Epub 2010 Oct 14.